Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Reviews

Tumor models for efficacy determination

Beverly A. Teicher
Beverly A. Teicher
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-06-0391 Published October 2006
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Mean survival time of mice inoculated with various numbers of murine L1210 leukemia cells injected i.p. or i.v. These data form the basis for the in vivo bioassay method for determining the number of L1201 cells surviving after treatment of L1210 tumor–bearing mice with therapy. From these survival curves, it was determined that (i) from i.p. inoculation, L1210 cell generation time = 0.55 day; lethal number of L1210 cells = 1.5 × 109; and (ii) from i.v. inoculation, L1210 cell generation time = 0.43 day (adapted from ref. 13).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Schematic representation of the calculation of tumor growth delay in days is shown illustrating the log-linear relationship between tumor volume increase and time. Tumor growth delay is usually calculated when control tumors reach a volume of 500 or 1,000 mm3.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Survival of EMT-6 mouse mammary tumor cells located in various tissues of BALB/c mice treated with a single dose of cyclophosphamide (100, 300, or 500 mg/kg). The mice were treated with cyclophosphamide on day 7 post tumor cell implant and the tissues were excised on day 8. Plating efficiency of tumor cells from untreated control mice was set at a surviving fraction of 1.0. There is a log-linear relationship between tumor cell killing and drug dose. The large variation in response of the tumor cells to the drug depending on tissue location is evident (adapted from ref. 26).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Growth delay of the mouse Lewis lung carcinoma produced by a range of doses of gemcitabine (i.p., days 7, 10, and 13) alone or with navelbine (15 mg/kg total dose; 10 mg/kg on day 7 and 5 mg/kg on day 14). The shaded area is the envelope of additivity calculated from dose-response curves for gemcitabine and navelbine administered as single agents using the isobologram method. Bars, SE (adapted from ref. 88).

PreviousNext
Back to top
Molecular Cancer Therapeutics: 5 (10)
October 2006
Volume 5, Issue 10
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Tumor models for efficacy determination
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tumor models for efficacy determination
Beverly A. Teicher
Mol Cancer Ther October 1 2006 (5) (10) 2435-2443; DOI: 10.1158/1535-7163.MCT-06-0391

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Tumor models for efficacy determination
Beverly A. Teicher
Mol Cancer Ther October 1 2006 (5) (10) 2435-2443; DOI: 10.1158/1535-7163.MCT-06-0391
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Solid Tumors
    • Human Tumor Xenografts
    • “Labeled” Tumor Models
    • Transgenic Tumor Models
    • Dose, Schedule, and Combination Regimens
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Targeting STAT3 with PROTACs and Next-Generation ASOs
  • Transcription Factors in AML
  • Patient Selection Strategies for Antibody–Drug Conjugates
Show more Reviews
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement